Biogened (WAR:BGD) ROCE %: 26.53% (As of Mar. 2026)


WAR:BGD Biogened SA WAR:BGD
68 GF Score
Price zł18.40
GF Value zł23.80
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biogened ROCE %?

Biogened WAR:BGD 68 ROCE % is 26.53% as of Mar. 2026. GuruFocus rates WAR:BGD with a GF Score™ of 68/100 and a GF Value™ of zł23.80 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biogened's annualized ROCE % for the quarter that ended in Mar. 2026 was 26.53%.

Biogened  (WAR:BGD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biogened ROCE % Related Terms

Biogened ROCE % Historical Data

* Premium members only.

The historical data trend for Biogened's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogened ROCE % Chart

Biogened Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.18 17.89 18.23 16.59 13.12

Biogened Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.26 16.92 3.10 10.92 26.53
WAR:BGD
68GF Score
Biogened SA WAR:BGD
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogened ROCE % Calculation

Biogened's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=8.277/( ( (86.405 - 22.229) + (87.235 - 25.266) )/ 2 )
=8.277/( (64.176+61.969)/ 2 )
=8.277/63.0725
=13.12 %

Biogened's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=17.064/( ( (87.235 - 25.266) + (95.692 - 29.043) )/ 2 )
=17.064/( ( 61.969 + 66.649 )/ 2 )
=17.064/64.309
=26.53 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 26.53% mean?
Biogened (WAR:BGD) has a ROCE % of 26.53% as of Mar. 2026.
Is Biogened's ROCE % too high?
Biogened's current ROCE % is 26.53%. The Drug Manufacturers industry median ROCE % is 7.03. Biogened's value of 26.53% is 277.4% above this industry median. Overall, Biogened has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's ROCE % compare to ZTS and UTHR?
Biogened's ROCE % of 26.53% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Biogened's value of 26.53% is 277.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogened's current ROCE % of 26.53% is 277.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current ROCE % is 26.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.80, compared to a current price of zł18.40 — trading 22.7% below its estimated fair value. The current ROCE % is 26.53% and 277.4% above the Drug Manufacturers industry median of 7.03. Biogened's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Biogened (WAR:BGD), the current ROCE % is 26.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł18.40 is trading 22.7% below its estimated GF Value™ of zł23.80. GuruFocus considers Biogened to be Modestly Undervalued.

Key valuation signals for WAR:BGD:

  • ROCE %: 26.53%
  • GF Value™: zł23.80 vs. price of zł18.40 (22.7% below fair value)
  • GF Score™: 68/100 with 3 warning signs
  • Industry Position: 277.4% above the Drug Manufacturers median

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
68GF Score

Get the complete analysis for WAR:BGD

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł18.40
Price
zł23.80
GF Value